{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"description":"Venous blood samples were drawn for analysis of ADAs to GEN3014 and daratumumab. In the GEN3014 arm, participants were tested for anti-GEN3014-antibodies; in the daratumumab arm, participants were tested for anti-daratumumab-antibodies.","groups":[{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG000","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG001","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Immunogenicity Analysis Set included all enrolled participants who received at least 1 dose of trial drug and had baseline ADA, and at least 1 evaluable on-treatment ADA sample. Overall number of participants analysed = participants evaluable for the OM.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 22 up to a maximum of approximately 23.9 months (cycles = 28 days)","title":"Expansion Part B: Number of Participants With Anti-GEN3014 Antibodies and Anti-Daratumumab Antibodies","type":"SECONDARY","unitOfMeasure":"Participants"}